HeLa (Human epithelial carcinoma cell line) Nuclear Lysate (ab14655)
- Product nameHeLa (Human epithelial carcinoma cell line) Nuclear LysateSee all HeLa lysates ...
- General notesWe recommend aliquoting the extracts into single-use fractions and then storing them.
- Tested applicationsWB, EMSA more details
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
- Storage bufferpH: 7.90
Constituents: 0.48% HEPES, 20% Glycerol, 0.01% Magnesium chloride, 0.077% DTT, 0.004% EGTA, 2.05% Sodium chloride, 1% NP-40
Note: With Protease inhibitors
- Concentration information loading...
- Research Areas
- BackgroundHeLa cells are human epithelial cells from a fatal cervical carcinoma. The cell line was derived from cervical cancer cells taken from Henrietta Lacks, in 1951. Horizontal gene transfer from human papillomavirus 18 (HPV18) to human cervical cells created the HeLa genome which is different from either parent genome in various ways including its number of chromosomes. HeLa cells have a modal chromosome number of 82, with 4 copies of chromosome 12 and 3 copies of chromosomes 6, 8, and 17. HeLa cells are adherent cells (they stick to surfaces) and maintain contact inhibition in vitro.
Our Abpromise guarantee covers the use of ab14655 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: Use at an assay dependent dilution.|
|EMSA||EMSA: Use at an assay dependent dilution. PubMed: 12075007|
References for HeLa (Human epithelial carcinoma cell line) Nuclear Lysate (ab14655)
This product has been referenced in:
- Weitzel LR et al. Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. Breast Cancer Res Treat 124:297-305 (2010). WB . Read more (PubMed: 20087651) »